var data={"title":"Avian influenza virus vaccine (H5N1) (United States: Availability limited to CDC distribution from strategic national stockpile in consultation with local health department): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Avian influenza virus vaccine (H5N1) (United States:&nbsp;Availability limited to&nbsp;CDC&nbsp;distribution from strategic national stockpile in consultation with local health department): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/324199?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4598869\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Vaccine;</li>\n      <li>\n        Vaccine, Inactivated (Viral)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4598894\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Primary immunization: </b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">GlaxoSmithKline product (adjuvanted): Adults &ge;18 years: IM: 0.5 mL, followed by a second 0.5 mL dose administered 21 days later</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sanofi Pasteur product: Adults 18 to 64 years: IM: 1 mL, followed by second 1 mL dose administered approximately 28 days later (acceptable range: 21 to 35 days)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50990237\" class=\"block dora drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50987572\" class=\"block doha drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50539486\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Primary immunization:</b> GlaxoSmithKline product (adjuvanted): Children &ge;6 months and Adolescents: IM: 0.25 mL, followed by a second 0.25 mL dose administered 21 days later.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51159580\" class=\"block dorp drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Pediatric)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51159581\" class=\"block dohp drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Pediatric)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4598899\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injection, emulsion [monovalent]: GlaxoSmithKline product: Adjuvanted Hemagglutinin [A/Indonesia/05/2005 (H5N1)] 3.75 mcg/0.5 mL (5 mL) [contains egg protein, polysorbate 80, and thimerosal]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injection, suspension [monovalent]: Sanofi Pasteur product: Hemagglutinin [A/Vietnam/1203/2004 (H5N1)] 90 mcg/mL (5 mL) [contains chicken and egg protein, porcine gelatin, and thimerosal]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4598867\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22803117\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Products will not be commercially available; distribution will be limited as part of the US Strategic National Stockpile.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11233933\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:0em;display:inline\">Commercial distribution is not planned. The vaccine will be included as part of the U.S. Strategic National Stockpile. It will be distributed by public health officials if needed. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4598895\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">For IM administration only. Shake well prior to use. Inspect for particulate matter and discoloration prior to administration. Administer into the deltoid muscle to older children and adults; administer into the anterolateral thigh for infants and small children. Do not mix with other vaccines or injections; separate needles and syringes should be used for each injection (ACIP [Kroger 2017]). To prevent syncope related injuries, adolescents and adults should be vaccinated while seated or lying down (ACIP [Kroger 2017]). US law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, and the administering person's name, title, and address be entered into the patient's permanent medical record.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">GlaxoSmithKline product (adjuvanted): If vaccine is stored under refrigeration after mixing, bring to room temperature prior to administration (minimum 15 minutes).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">For patients at risk of hemorrhage following intramuscular injection, the vaccine should be administered intramuscularly if, in the opinion of the physician familiar with the patient's bleeding risk, the vaccine can be administered by this route with reasonable safety. If the patient receives antihemophilia or other similar therapy, intramuscular vaccination can be scheduled shortly after such therapy is administered. A fine needle (23 gauge or smaller) can be used for the vaccination and firm pressure applied to the site (without rubbing) for at least 2 minutes. The patient should be instructed concerning the risk of hematoma from the injection. Patients on anticoagulant therapy should be considered to have the same bleeding risks and treated as those with clotting factor disorders (ACIP [Kroger 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4598872\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Influenza A (H5N1) prevention:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">GlaxoSmithKline product (adjuvanted): For active immunization of persons &ge;6 months of age at increased risk of exposure to the influenza A (H5N1) virus subtype contained in the vaccine</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sanofi Pasteur product: For active immunization of persons 18-64 years of age at increased risk of exposure to the influenza A (H5N1) virus subtype contained in the vaccine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4598861\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Influenza A virus vaccine (H5N1) may be confused with the nonavian or avian strains of influenza virus vaccine</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4598881\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>All serious adverse reactions must be reported to the U.S. Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967 or online at <a target=\"_blank\" href=\"https://vaers.hhs.gov/esub/index&amp;token=8m3rK0tzv73hmwLVujPJP0lWL2FxLWQizZTxo5kD83IMEaCGiDnUFaD+0my2cUJQ&amp;TOPIC_ID=8922\" target=\"_blank\">https://vaers.hhs.gov/esub/index</a>.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (3% to 35%), fatigue (34%), shivering (17%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Diaphoresis (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Pain at injection site (74% to 83%), tenderness at injection site (70%), erythema at injection site (9% to 20%), swelling at injection site (10% to 15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Myalgia (45%), arthralgia (25%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (10%), diarrhea (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Itching at injection site (2%), burning sensation at injection site (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Nasal congestion (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%: Celiac disease, cerebrovascular accident, convulsions, cranial nerve palsy (IV), Crohn&rsquo;s disease, erythema nodosum, facial paralysis, giant-cell arteritis, hepatitis, injection site reaction, malignant neoplasm of thyroid, organ transplant rejection (corneal), polymyalgia rheumatica, psoriasis, pulmonary embolism, radiculopathy, rheumatoid arthritis, rheumatoid lung, skin rash</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4598877\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">GlaxoSmithKline product (adjuvanted): Known severe allergic reactions (eg, anaphylaxis) to any component of the vaccine, including egg protein, or after a previous dose of an influenza vaccine.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Sanofi Pasteur product: There are no contraindications listed in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4598878\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Syncope: Syncope has been reported with use of injectable vaccines and may be accompanied by transient visual disturbances, weakness, or tonic-clonic movements. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acute illness: The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Defer administration in patients with moderate or severe acute illness (with or without fever); vaccination should not be delayed for patients with mild acute illness (with or without fever) (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding disorders: Use with caution in patients with bleeding disorders (including thrombocytopenia); bleeding/hematoma may occur from IM administration; if the patient receives antihemophilia or other similar therapy, IM injection can be scheduled shortly after such therapy is administered (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Guillain-Barr&eacute; syndrome: Use with caution in patients with a history of Guillain-Barr&eacute; syndrome (GBS); patients with history of GBS have a greater likelihood of developing GBS than those without. Relationship to this influenza vaccine formulation is not known. As a precaution, the ACIP recommends that patients with a history of GBS and who are at low risk for severe influenza complications, and patients known to have experienced GBS within 6 weeks following previous vaccination should generally not be vaccinated (consider influenza antiviral chemoprophylaxis in these patients). The benefits of vaccination may outweigh the potential risks in persons with a history of GBS who are also at high risk for complications of influenza (CDC 2013). Recent studies of patients who received the trivalent inactivated influenza vaccine or the monovalent H1N1 influenza vaccine have shown the risk of GBS is lower with vaccination than with influenza infection (Baxter 2013; Greene 2013; Kwong 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anticoagulant therapy: Use with caution in patients receiving anticoagulant therapy; bleeding/hematoma may occur from IM administration (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vaccines: In order to maximize vaccination rates, the ACIP recommends simultaneous administration (ie, &gt;1 vaccine on the same day at different anatomic sites) of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single clinic visit, unless contraindications exist. The ACIP prefers each dose of a specific vaccine in a series come from the same manufacturer when possible; however vaccination should not be deferred because a specific brand name is unavailable (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Altered immunocompetence: Consider deferring immunization during periods of severe immunosuppression (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy [including high-dose corticosteroids]); may have a reduced response to vaccination. In general, household and close contacts of persons with altered immunocompetence may receive all age appropriate vaccines. Inactivated vaccines should be administered &ge;2 weeks prior to planned immunosuppression when feasible; inactivated vaccines administered during chemotherapy should be readministered after immune competence is regained (ACIP [Kroger 2017]; IDSA [Rubin, 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Sanofi Pasteur product has not been evaluated in patients &ge;65 years of age</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Apnea has occurred following intramuscular vaccine administration in premature infants; consider clinical status implications. In general, preterm infants should be vaccinated at the same chronological age as full-term infants (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Chicken egg protein: Product may be manufactured with chicken egg protein.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thimerosal: Product may contain thimerosal; hypersensitivity reactions may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Antipyretics: Antipyretics have not been shown to prevent febrile seizures; antipyretics may be used to treat fever or discomfort following vaccination (ACIP [Kroger 2017]). One study reported that routine prophylactic administration of acetaminophen prior to vaccination to prevent fever decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (ACIP [Kroger 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299518\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4598884\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8922&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Patients should receive inactivated vaccines prior to initiation of belimumab therapy whenever possible, due to the risk for an impaired response to the vaccine during belimumab therapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting fingolimod. If vaccinated during fingolimod therapy, revaccinate 2 to 3 months after fingolimod discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<b> Exceptions: </b>Cytarabine (Liposomal).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: May diminish the therapeutic effect of Vaccines (Inactivated).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4598873\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (Sanofi Pasteur product) (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4598874\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies using the H5N1 vaccine GlaxoSmithKline adjuvanted product; animal reproduction studies have not been conducted with the Sanofi Pasteur product. Inactivated viral vaccines have not been shown to cause increased risks to the fetus (ACIP [Kroger 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12704133\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if this vaccine is excreted into breast milk. Administration does not affect the safety of breastfeeding for the mother or the infant (ACIP [Kroger 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12704134\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor for anaphylaxis and syncope for 15 minutes following administration (ACIP [Kroger 2017]). If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4598888\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">The GlaxoSmithKline product is an adjuvanted monovalent split virus (inactivated) preparation of the type A, subtype H5N1 avian strain of influenza virus (A/Indonesia/05/2005)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">The Sanofi Pasteur product is a monovalent, split virus (inactivated) preparation of the type A, subtype H5N1 avian strain of influenza virus (A/Vietnam/1203/2004)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Both promote active immunity to influenza A H5N1 (avian).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4598890\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;display:inline\">Onset of action:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">GlaxoSmithKline product (adjuvanted): Fourfold increase in antibody titers (measured by hemagglutination inhibition [HI]) occurred in up to 90% of patients 18-64 years of age and 74% of patients &ge;65 years of age 21 days after the second dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Sanofi Pasteur product: Fourfold increase in antibody titers (measured by HI) occurred in up to 58% of patients 28 days after the second dose (Treanor, 2006).</p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z, et al; Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus. Update on avian influenza A (H5N1) virus infection in humans. <i>N Engl J Med</i>. 2008;358(3):261-273.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/avian-influenza-virus-vaccine-h5n1-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-drug-information/abstract-text/18199865/pubmed\" target=\"_blank\" id=\"18199865\">18199865</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baxter R, Bakshi N, Fireman B, et al. Lack of association of Guillain-Barre syndrome with vaccinations. <i>Clin Infect Dis</i>. 2013;57(2):197-204.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/avian-influenza-virus-vaccine-h5n1-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-drug-information/abstract-text/23580737/pubmed\" target=\"_blank\" id=\"23580737\">23580737</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Greene SK, Rett MD, Vellozzi C, et al. Guillain-Barr&eacute; Syndrome, Influenza Vaccination, and Antecedent Respiratory and Gastrointestinal Infections: A Case-Centered Analysis in the Vaccine Safety Datalink, 2009-2011. <i>PLoS One</i>. 2013;8(6):e67185.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/avian-influenza-virus-vaccine-h5n1-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-drug-information/abstract-text/23840621/pubmed\" target=\"_blank\" id=\"23840621\">23840621</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Influenza A (H5N1) virus monovalent vaccine, adjuvanted [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; September 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Influenza virus vaccine, H5N1 [prescribing information]. Swiftwater, PA: Sanofi Pasteur; April 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kroger AT, Duchin J, Vazquez M. General Best Practice Guidelines for Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). <a href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf\" target=\"_blank\">https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf</a>. Accessed April 4, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kwong JC, Vasa PP, Campetelli MA, et al. Risk of Guillain-Barr&eacute; syndrome after seasonal influenza vaccination and influenza health-care encounters: a self-controlled study. <i>Lancet Infecti Dis</i>. 2013;13(9):769-776.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/avian-influenza-virus-vaccine-h5n1-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-drug-information/abstract-text/23810252/pubmed\" target=\"_blank\" id=\"23810252\">23810252</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Langley JM, Risi G, Caldwell M, et al. Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study. <i>J Infect Dis</i>. 2011;203(12):1729-1738.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/avian-influenza-virus-vaccine-h5n1-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-drug-information/abstract-text/21606531/pubmed\" target=\"_blank\" id=\"21606531\">21606531</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <i>OSHA Guidance Update on Protecting Employees From Avian Flu (Avian Influenza) Viruses,</i> Washington, DC: US Department of Labor, Occupational Safety and Health Administration; 2006. Available at <a href=\"http://www.osha.gov/OshDoc/data_AvianFlu/avian_flu_guidance_english.pdf\" target=\"_blank\">http://www.osha.gov/OshDoc/data_AvianFlu/avian_flu_guidance_english.pdf </a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prymula R, Siegrist CA, Chlibek R, et al, &ldquo;Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,&rdquo; <i>Lancet</i>, 2009, 374(9698):1339-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/avian-influenza-virus-vaccine-h5n1-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-drug-information/abstract-text/19837254/pubmed\" target=\"_blank\" id=\"19837254\">19837254</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. <i>Clin Infect Dis</i>. 2014;58(3):e44-e100.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/avian-influenza-virus-vaccine-h5n1-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-drug-information/abstract-text/24311479/pubmed\" target=\"_blank\" id=\"24311479\">24311479</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Treanor JJ, Campbell JD, Zangwill KM, et al, &ldquo;Safety and Immunogenicity of an Inactivated Subvirion Influenza A (H5N1) Vaccine,&rdquo; <i>N Engl J Med</i>, 2006, 354(13):1343-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/avian-influenza-virus-vaccine-h5n1-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-drug-information/abstract-text/16571878/pubmed\" target=\"_blank\" id=\"16571878\">16571878</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zangwill KM, Treanor JJ, Campbell JD, et al, &quot;Evaluation of the Safety and Immunogenicity of a Booster (Third) Dose of Inactivated Subvirion H5N1 Influenza Vaccine in Humans,&quot;<i>J Infect Dis</i>, 2008, 197(4):580-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/avian-influenza-virus-vaccine-h5n1-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-drug-information/abstract-text/18237269/pubmed\" target=\"_blank\" id=\"18237269\">18237269</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8922 Version 82.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F4598869\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F4598894\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Adult)\" href=\"#F50990237\" class=\"outlineLink\">Dosing: Renal Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Adult)\" href=\"#F50987572\" class=\"outlineLink\">Dosing: Hepatic Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F50539486\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Pediatric)\" href=\"#F51159580\" class=\"outlineLink\">Dosing: Renal Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Pediatric)\" href=\"#F51159581\" class=\"outlineLink\">Dosing: Hepatic Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F4598899\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F4598867\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F22803117\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F11233933\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F4598895\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F4598872\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F4598861\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F4598881\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F4598877\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F4598878\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299518\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F4598884\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F4598873\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F4598874\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F12704133\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F12704134\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F4598888\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F4598890\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8922|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div>","javascript":null}